Jack Lambert, MD
Urology · Onancock, VANPI 1518128453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,643 and has fallen 98.4% since, to $27 in 2025. That places this record below the midpoint for urology clinicians in VA, where the typical reported total is $2,551.
Across 102 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$240
- Astellas Pharma US Inc$205
- Bayer$179
- Johnson & Johnson$150
- Endo Pharmaceuticals Inc.$117
- Pfizer$111
- plus $873 from 20 others
Across 5 payments — averaging $6301.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$32K
What the payments were for
- Food & beverage$1,79596%
- Education$804%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 16 | $240 |
| Astellas Pharma US Inc | 12 | $205 |
| Bayer | 14 | $179 |
| Johnson & Johnson | 3 | $150 |
| Endo Pharmaceuticals Inc. | 8 | $117 |
| Pfizer | 7 | $111 |
| Antares Pharma, Inc. | 4 | $96 |
| Travere Therapeutics, Inc. | 5 | $91 |
| Sun Pharmaceutical Industries Inc. | 2 | $75 |
| Olympus America Inc. | 4 | $74 |
| Photocure Inc | 2 | $70 |
| Coloplast | 5 | $69 |
| Procept Biorobotics Corporation | 2 | $57 |
| Dornier Medtech America, Inc | 1 | $51 |
| KARL Storz Endoscopy-america | 3 | $49 |
| AbbVie(2 entities) | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Neotract Inc. | 2 | $27 |
| Novartis | 1 | $25 |
| Blue Earth Diagnostics | 1 | $24 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $20 |
| Abbott | 1 | $18 |
| Dentsply IH Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,875 in reported general payments places this provider in the 40th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $314,683 |
| MyrbetriqMirabegron | 36 | $23,765 |
| Tolterodine Tartrate ErTolterodine Tartrate | 70 | $10,213 |
| Tamsulosin Hcl | 477 | $8,635 |
| Oxybutynin Chloride ErOxybutynin Chloride | 304 | $6,602 |
| Potassium Citrate ErPotassium Citrate | 37 | $4,741 |
| Finasteride | 256 | $3,486 |
| Testosterone | 13 | $3,386 |
| Estradiol | 43 | $2,508 |
| Solifenacin Succinate | 46 | $2,470 |
| Dutasteride | 30 | $1,211 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 54 | $1,084 |
| Trospium Chloride | 15 | $1,074 |
| Testosterone Cypionate | 29 | $814 |
| Oxybutynin Chloride | 82 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $205 | $338,44860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 300 urology providers in Virginia.
Other urology in Onancock
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Patrick WhelanSuffolk$114K
- Jennifer Miles-ThomasVa Beach$101K
- Charles DanielRoanoke$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.